Propella Therapeutics has been funded by its founders and associated individuals and entities. Propella was spun-out of Vizuri Health Sciences in 2020 as a stand-alone entity dedicated to the accelerated development of best-in-class therapies. PRL-02, a long-acting depot injection, utilizes an innovative and patented prodrug of abiraterone, a proven active pharmaceutical ingredient (API) used in oral drugs. PRL-02 clinical studies will begin in 2Q 2021. Topical CGS-200-5 has successfully completed a Phase 2 study for the management of pain due to osteoarthritis (OA) of the knee and is Phase 3 ready.
Propella is seeking like-minded investors who share our vision to bring innovative therapies to market.
The Arthritis Foundation is the arthritis community’s Champion of Yes. The Foundation’s goal is to chart a winning course, guiding families in developing personalized plans for living a full life while striving for a cure. The Arthritis Foundation helps people living with arthritis through its strategic pillars of scientific discovery, help and support, advocacy and access, and juvenile arthritis.
National Cancer Institute (NCI)
The National Cancer Institute (NCI) is the federal government’s principal agency for cancer research and training. The Genitourinary Malignancies Branch of the NCI focuses on investigating the biology of genitourinary (GU) cancers, developing new strategies for treating those cancers, and evaluating new therapeutic approaches through science-driven research.
Joanneum Research (JR)
JR’s Institute for Biomedicine and Health Sciences is a link between basic medical research and industrial applications acting as an interdisciplinary provider of total solutions in the fields of medicine, pharmacy, medical technology and health care research. As a service to the pharmaceutical industry, they investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of new drugs as well as the bioequivalence (BE) of new pharmaceutical formulations. They perform preclinical ex vivo and in vivo, as well as clinical in vivo, studies using their patented Open Flow Microperfusion methodology.
We value and wish to hear from parties who share our motivation to accelerate development of life-changing therapies.
discuss the Propella potential
To learn more about investment or partnering opportunities, contact:
Brendan Griffin, CFO